Shin Kawamata

Shin Kawamata, CEO of Cyto-Facto Inc., discusses revolutionizing cell manufacturing by merging public sector support with commercial viability. He emphasizes the importance of Quality by Design strategies in cell therapy manufacturing and shares insights on scaling up cell therapies efficiently through automation, digitalization, and QbD. The podcast delves into specific quality requirements for mass culture of stem cells and CAR-T therapy, highlighting the significance of maintaining youth in CAR-T therapy.